Excessive exercise elicits poly (ADP-ribose) Polymerase-1 activation and global protein PARylation driving muscle dysfunction and performance impairment
Excessive exercise combined with inadequate recovery time may trigger fatigue, performance impairment, and ultimately the overtraining syndrome. The intramyocellular mechanisms involved in the overtraining syndrome remain only partially known. Here, we combined multi-omics analyses from isogenic BXD mouse strains with a mouse model of overtraining and excessive exercise protocol in mice and humans to evaluate the molecular mechanism involved in the performance impairment induced by excessive exercise. We identified that BXD mouse strains with elevated levels of Parp1 gene expression in the skeletal muscle displayed features like overtraining syndrome and abnormal muscle genetic signature. High PARP1 protein content and aberrant PARylation of proteins were detected in the skeletal muscle of overtrained, but not in trained mice. Overtraining syndrome reduced mitochondrial function promoted by exercise training, induced muscle hyperalgesia, reduced muscle fiber size and promoted a similar gene signature of myopathy and atrophy models. Short periods of excessive exercise also increased PARylation in the skeletal muscle of mice and healthy subjects. The pharmacological inhibition of PARP1, using Olaparib, and genetic Parp1 ablation, preserved muscle fiber morphology and protected against physical performance impairment and other symptoms of the overtraining syndrome in mice. In conclusion, PARP1 excessive activation is related to muscle abnormalities led by long or short periods of excessive exercise, and here we suggest that PARP1 is a potential target in the treatment and prevention of overtraining syndrome.
Authors
- Renata Rosseto Braga (ORCID: https://orcid.org/0000-0002-2269-7000)
- Matheus Biscaro Rocha (ORCID: https://orcid.org/0000-0002-8766-2984)
- Adelino Sánchez Ramos da Silva (ORCID: https://orcid.org/0000-0002-9679-8357)
- José Rodrigo Pauli (ORCID: https://orcid.org/0000-0002-6129-1521)
- Marcelo A. Mori (ORCID: https://orcid.org/0000-0001-7112-5263)
- Raul Gobato Costa
- Carlos K. Katashima (ORCID: https://orcid.org/0000-0002-3908-127X)
- Rafael S. Brícola (ORCID: https://orcid.org/0000-0002-8982-1096)
- Eduardo R. Ropelle
- Beatriz Franco (ORCID: https://orcid.org/0000-0003-2197-304X)
- Fernanda S. Carneiro (ORCID: https://orcid.org/0000-0002-5776-1519)
- Maressa Chagas Oliveira (ORCID: https://orcid.org/0000-0002-6610-1125)
- Andrea Maculano Esteves (ORCID: https://orcid.org/0000-0003-2435-5335)
- Ana Paula Morelli (ORCID: https://orcid.org/0000-0002-5351-334X)
- Graciana de Azambuja (ORCID: https://orcid.org/0000-0003-3898-6736)
- Filip J. Larsen (ORCID: https://orcid.org/0000-0002-1343-8656)
- Bárbara Crisol (ORCID: https://orcid.org/0000-0003-2026-2844)
- Dennys E. Cintra (ORCID: https://orcid.org/0000-0002-7954-5630)
- J A Scylas
Institutions
- Universidade de Ribeirão Preto (BR)
- Universidade de São Paulo (BR)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Swedish School of Sport and Health Sciences (SE)
- Clinics Hospital of Ribeirão Preto (BR)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1016/j.molmet.2025.102135
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico